ENXTPA:ABVX

Stock Analysis Report

Executive Summary

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops, markets, and commercializes treatments for the treatment of autoimmune diseases, viral infections, and cancer in France.


Snowflake Analysis

High growth potential with imperfect balance sheet.

Share Price & News

How has ABIVAX Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABVX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

20.0%

ABVX

12.2%

FR Biotechs

2.5%

FR Market


1 Year Return

88.7%

ABVX

-31.1%

FR Biotechs

-18.6%

FR Market

Return vs Industry: ABVX exceeded the French Biotechs industry which returned -31.1% over the past year.

Return vs Market: ABVX exceeded the French Market which returned -18.6% over the past year.


Shareholder returns

ABVXIndustryMarket
7 Day20.0%12.2%2.5%
30 Day16.4%-18.0%-17.0%
90 Day-28.1%-27.2%-25.0%
1 Year88.7%88.7%-31.0%-31.1%-15.7%-18.6%
3 Year143.1%143.1%-65.9%-66.0%0.8%-8.6%
5 Yearn/a-68.5%-68.7%10.8%-6.9%

Price Volatility Vs. Market

How volatile is ABIVAX Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ABIVAX Société Anonyme undervalued compared to its fair value and its price relative to the market?

8.37x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABVX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABVX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABVX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ABVX is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABVX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABVX is overvalued based on its PB Ratio (8.4x) compared to the FR Biotechs industry average (2.4x).


Next Steps

Future Growth

How is ABIVAX Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

3.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABVX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.1%).

Earnings vs Market: ABVX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ABVX's is expected to become profitable in the next 3 years.

Revenue vs Market: ABVX's revenue (69.3% per year) is forecast to grow faster than the French market (3.5% per year).

High Growth Revenue: ABVX's revenue (69.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABVX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ABIVAX Société Anonyme performed over the past 5 years?

-17.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABVX is currently unprofitable.

Growing Profit Margin: ABVX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABVX is unprofitable, and losses have increased over the past 5 years at a rate of -17.1% per year.

Accelerating Growth: Unable to compare ABVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: ABVX has a negative Return on Equity (-146.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is ABIVAX Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ABVX's short term assets (€21.3M) exceed its short term liabilities (€14.2M).

Long Term Liabilities: ABVX's short term assets (€21.3M) exceed its long term liabilities (€19.5M).


Debt to Equity History and Analysis

Debt Level: ABVX's debt to equity ratio (104.2%) is considered high.

Reducing Debt: ABVX's debt to equity ratio has increased from 6.2% to 104.2% over the past 5 years.


Balance Sheet

Inventory Level: ABVX has a low level of unsold assets or inventory.

Debt Coverage by Assets: ABVX's debt is not covered by short term assets (assets are 1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ABVX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ABVX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ABIVAX Société Anonyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABVX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABVX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABVX's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Hartmut Ehrlich

6.33s

Tenure

€396,775

Compensation

Prof. Dr. Hartmut J. Ehrlich, M.D. has been the Chief Executive Officer of ABIVAX S.A. since December 04, 2013. Prof. Dr. Ehrlich is a physician and global leader with 30 years in academia and in the biop ...


CEO Compensation Analysis

Compensation vs Market: Hartmut's total compensation ($USD436.02K) is about average for companies of similar size in the French market ($USD458.92K).

Compensation vs Earnings: Hartmut's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Philippe Pouletty
Founder & Chairman5.33yrsno datano data
Hartmut Ehrlich
Chief Executive Officer6.33yrs€396.78kno data
Didier Blondel
VP, CFO & Board Secretary3.25yrsno datano data
Raquel Lizarraga
Investor Relations Managerno datano datano data
Anne Pascard
Human Resources Managerno datano datano data
Pierre Courteille
VP, Chief Commercial Officer & VP of Business Developmentno datano datano data
Jean-Marc Steens
VP & Chief Medical Officerno datano datano data
Alexandra Pearce
VP & Head of Regulatory Affairs1.92yrsno datano data
Alain Chevallier
Senior Advisor3.25yrsno datano data

3.3yrs

Average Tenure

Experienced Management: ABVX's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philippe Pouletty
Founder & Chairman5.33yrsno datano data
Joy Amundson
Independent Director5.75yrs€3.08kno data
Christian Pierret
Director6.08yrs€5.55kno data
Jean-Jacques Bertrand
Independent Director6.08yrs€6.02kno data
Christoph Huber
Member of Scientific Advisory Boardno datano datano data
Claude Bertrand
Member of Supervisory Board0.50yr€1.39kno data
Jean-Paul Prieels
Member of Scientific Advisory Boardno datano datano data
Luc Teyton
Member of Scientific Advisory Boardno datano datano data
Corinna Bonsen-Thomas
Independent Director2.75yrs€5.46kno data
Ian McGowan
Chairman of Scientific Advisory Board1.83yrsno datano data

5.3yrs

Average Tenure

64yo

Average Age

Experienced Board: ABVX's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

ABIVAX Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ABIVAX Société Anonyme
  • Ticker: ABVX
  • Exchange: ENXTPA
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €206.602m
  • Shares outstanding: 12.12m
  • Website: https://www.abivax.com

Number of Employees


Location

  • ABIVAX Société Anonyme
  • 5, rue de la Baume
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABVXENXTPA (Euronext Paris)YesCommon StockFREURJun 2015
ABVXpBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURJun 2015
0RA9LSE (London Stock Exchange)YesCommon StockGBEURJun 2015
AAVX.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2015
2X1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2015

Biography

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops, markets, and commercializes treatments for the treatment of autoimmune diseases, viral infections, and cancer in France. Its principal products include ABX 464 that is in Phase IIb clinical trials for the treatment of anti-inflammatory and ulcerative colitis; and Phase IIa clinical trial for the treatment of Crohn’s and rheumatoid arthritis diseases, as well as has completed Phase IIa clinical trial for the treatment of viral disease in patients with HIV. It also develops ABX 196, an art immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company’s pre-clinical programs ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. The company was incorporated in 2013 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/01 04:56
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.